[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 154
Citations 0
Comment & Response
August 2016

Caregiver Perspectives on End-of-Life Experiences of Patients With Left Ventricular Assist Devices—Reply

Author Affiliations
  • 1Section of Advanced Heart Failure and Transplantation, Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado
  • 2Colorado Cardiovascular Outcomes Research Consortium, University of Colorado School of Medicine, Aurora, Colorado
  • 3Division of Geriatric Medicine, University of Colorado School of Medicine, Aurora, Colorado

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2016;176(8):1231-1232. doi:10.1001/jamainternmed.2016.3735

In Reply We appreciate the thoughtful response to our work1 from Drs Nakada and Arakawa. We agree that the informed consent process should be robust and ongoing when discussing left ventricular assist device (LVAD) therapy with patients and their caregivers. We also wholeheartedly agree that discussions around dying with an LVAD—especially when patients are being implanted under the destination therapy (DT) indication—should be discussed prior to implant or as medical realities allow. However, going beyond stating this should occur, we believe the real challenge is how to have these conversations with patients and caregivers. This is true not just for LVADs but for all complicated technological therapies that alter the dying process.